Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series

CD19-directed chimeric antigen receptor (CAR) T cell therapy is a very promising and effective therapy for relapsed or refractory aggressive B cell lymphomas.1,2 However, approximately 60% to 70% of patients with aggressive B cell lymphoma do not achieve a durable remission.3 One major mechanism of resistance to CAR T cell therapy is the limited persistence of CAR T cells after infusion. This could be partly mediated by the upregulation of programmed cell death protein 1 (PD-1) expression on CAR T cells leading to immune exhaustion and subsequent disease relapse.

Source: Clinical Lymphoma, Myeloma and Leukemia - December 25, 2019 Category: Hematology Authors: Swetha Kambhampati, Lissa Gray, Bita Fakhri, Mimi Lo, Khoan Vu, Shagun Arora, Lawry Kaplan, Weiyun Z. Ai, Charalambos Andreadis Tags: Case Report Source Type: research